Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer

[1] Ahr A(2002)Identification of high risk breast-cancer patients by gene expression profiling Lancet 359 131-132

[2] Karn T(2007)High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates Cancer Res 67 10669-10676

[3] Solbach C(2006)Substrate reduction therapy in the infantile form of Tay-Sachs disease Neurology 66 278-280

[4] Seiter T(2007)Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial Lancet Oncol 8 1071-1078

[5] Strebhardt K(2007)Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders Expert Opin Pharmacother 8 427-435

[6] Holtrich U(1993)Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs J Natl Cancer Inst 85 632-639

[7] Alexe G(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-1513

[8] Dalgin GS(1989)Direct correlation between DNA topoisomerase II activity and ytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines Cancer Res 49 58-62

[9] Scanfeld D(2002)Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation Glycobiology 12 145-152

[10] Tamayo P(2002)Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis Cell Death Differ 9 693-695

[1] Ahr A(2002)Identification of high risk breast-cancer patients by gene expression profiling Lancet 359 131-132

[2] Karn T(2007)High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates Cancer Res 67 10669-10676

[3] Solbach C(2006)Substrate reduction therapy in the infantile form of Tay-Sachs disease Neurology 66 278-280

[4] Seiter T(2007)Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial Lancet Oncol 8 1071-1078

[5] Strebhardt K(2007)Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders Expert Opin Pharmacother 8 427-435

[6] Holtrich U(1993)Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs J Natl Cancer Inst 85 632-639

[7] Alexe G(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-1513

[8] Dalgin GS(1989)Direct correlation between DNA topoisomerase II activity and ytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines Cancer Res 49 58-62

[9] Scanfeld D(2002)Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation Glycobiology 12 145-152

[10] Tamayo P(2002)Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis Cell Death Differ 9 693-695